Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-trace').style.display = (document.getElementById('cakeErr67f75c6579684-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f75c6579684-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-code').style.display = (document.getElementById('cakeErr67f75c6579684-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-context').style.display = (document.getElementById('cakeErr67f75c6579684-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f75c6579684-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f75c6579684-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21462,
		&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21609,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21462,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21462,
	&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21609,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21462
$metaTitle = &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;
$metaKeywords = &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;
$metaDesc = &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs | Im4change.org</title>
    <meta name="description" content="
-Reuters



BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU fines Ranbaxy, others for blocking cheaper drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Reuters</div><p align="justify"><br /><em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.</p><p align="justify">The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.</p><p align="justify">The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. </p><p align="justify">Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.</p><p align="justify">In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.</p><p align="justify">&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.</p><p align="justify">&quot;The Commission will not tolerate such anticompetitive practices.&quot;</p><p align="justify">The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.</p><p align="justify">The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.</p><p align="justify">The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.</p><p align="justify">The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.</p><p align="justify">It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.</p><p align="justify">The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-trace').style.display = (document.getElementById('cakeErr67f75c6579684-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f75c6579684-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-code').style.display = (document.getElementById('cakeErr67f75c6579684-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-context').style.display = (document.getElementById('cakeErr67f75c6579684-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f75c6579684-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f75c6579684-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21462,
		&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21609,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21462,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21462,
	&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21609,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21462
$metaTitle = &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;
$metaKeywords = &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;
$metaDesc = &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs | Im4change.org</title>
    <meta name="description" content="
-Reuters



BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU fines Ranbaxy, others for blocking cheaper drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Reuters</div><p align="justify"><br /><em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.</p><p align="justify">The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.</p><p align="justify">The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. </p><p align="justify">Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.</p><p align="justify">In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.</p><p align="justify">&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.</p><p align="justify">&quot;The Commission will not tolerate such anticompetitive practices.&quot;</p><p align="justify">The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.</p><p align="justify">The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.</p><p align="justify">The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.</p><p align="justify">The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.</p><p align="justify">It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.</p><p align="justify">The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-trace').style.display = (document.getElementById('cakeErr67f75c6579684-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f75c6579684-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-code').style.display = (document.getElementById('cakeErr67f75c6579684-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f75c6579684-context').style.display = (document.getElementById('cakeErr67f75c6579684-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f75c6579684-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f75c6579684-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21462,
		&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21609,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21462,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21462,
	&#039;title&#039; =&gt; &#039;EU fines Ranbaxy, others for blocking cheaper drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Reuters
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21609,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21462
$metaTitle = &#039;LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs&#039;
$metaKeywords = &#039;Ranbaxy,medicines,generic drugs,Consumer Rights&#039;
$metaDesc = &#039;
-Reuters



BRUSSELS: Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Reuters&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;BRUSSELS: &lt;/em&gt;Nine drugmakers, including Denmark&#039;s Lundbeck and India&#039;s Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &amp;quot;pay-for-delay&amp;quot; deals lead to consumers paying as much as 20 percent more for their medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&amp;quot; said EU Competition Commissioner Joaquin Almunia.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The Commission will not tolerate such anticompetitive practices.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission fined Germany&#039;s Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India&#039;s No. 1 pharmaceutical company Ranbaxy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &amp;quot;a club&amp;quot; and &amp;quot;a pile of $$$&amp;quot; to be shared.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It said Lundbeck also bought generics&#039; stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The EU competition authority has two similar cases in the pipeline, involving Israel&#039;s Teva, French drugmaker Servier, Johnson &amp;amp; Johnson and Novartis. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs | Im4change.org</title>
    <meta name="description" content="
-Reuters



BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>EU fines Ranbaxy, others for blocking cheaper drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Reuters</div><p align="justify"><br /><em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.</p><p align="justify">The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.</p><p align="justify">The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. </p><p align="justify">Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.</p><p align="justify">In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.</p><p align="justify">&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.</p><p align="justify">&quot;The Commission will not tolerate such anticompetitive practices.&quot;</p><p align="justify">The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.</p><p align="justify">The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.</p><p align="justify">The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.</p><p align="justify">The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.</p><p align="justify">It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.</p><p align="justify">The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 21462,
		'title' => 'EU fines Ranbaxy, others for blocking cheaper drugs',
		'subheading' => '',
		'description' => '<div align="justify">
-Reuters
</div>
<p align="justify">
<br />
<em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
</p>
<p align="justify">
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.
</p>
<p align="justify">
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
</p>
<p align="justify">
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
</p>
<p align="justify">
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
</p>
<p align="justify">
&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.
</p>
<p align="justify">
&quot;The Commission will not tolerate such anticompetitive practices.&quot;
</p>
<p align="justify">
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
</p>
<p align="justify">
The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
</p>
<p align="justify">
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.
</p>
<p align="justify">
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.
</p>
<p align="justify">
It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
</p>
<p align="justify">
The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. 
</p>',
		'credit_writer' => 'The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 21609,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 21462,
	'metaTitle' => 'LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs',
	'metaKeywords' => 'Ranbaxy,medicines,generic drugs,Consumer Rights',
	'metaDesc' => '
-Reuters



BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...',
	'disp' => '<div align="justify">-Reuters</div><p align="justify"><br /><em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.</p><p align="justify">The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.</p><p align="justify">The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. </p><p align="justify">Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.</p><p align="justify">In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.</p><p align="justify">&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.</p><p align="justify">&quot;The Commission will not tolerate such anticompetitive practices.&quot;</p><p align="justify">The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.</p><p align="justify">The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.</p><p align="justify">The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.</p><p align="justify">The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.</p><p align="justify">It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.</p><p align="justify">The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 21462,
	'title' => 'EU fines Ranbaxy, others for blocking cheaper drugs',
	'subheading' => '',
	'description' => '<div align="justify">
-Reuters
</div>
<p align="justify">
<br />
<em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
</p>
<p align="justify">
The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.
</p>
<p align="justify">
The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. 
</p>
<p align="justify">
Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.
</p>
<p align="justify">
In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.
</p>
<p align="justify">
&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.
</p>
<p align="justify">
&quot;The Commission will not tolerate such anticompetitive practices.&quot;
</p>
<p align="justify">
The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.
</p>
<p align="justify">
The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.
</p>
<p align="justify">
The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.
</p>
<p align="justify">
The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.
</p>
<p align="justify">
It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.
</p>
<p align="justify">
The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. 
</p>',
	'credit_writer' => 'The Times of India, 19 June, 2013, http://timesofindia.indiatimes.com/business/india-business/EU-fines-Ranbaxy-others-for-blocking-cheaper-drugs/articleshow/20665502.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'eu-fines-ranbaxy-others-for-blocking-cheaper-drugs-21609',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 21609,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 21462
$metaTitle = 'LATEST NEWS UPDATES | EU fines Ranbaxy, others for blocking cheaper drugs'
$metaKeywords = 'Ranbaxy,medicines,generic drugs,Consumer Rights'
$metaDesc = '
-Reuters



BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.


The punishments follow a 2009 report...'
$disp = '<div align="justify">-Reuters</div><p align="justify"><br /><em>BRUSSELS: </em>Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.</p><p align="justify">The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said &quot;pay-for-delay&quot; deals lead to consumers paying as much as 20 percent more for their medicines.</p><p align="justify">The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. </p><p align="justify">Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership.</p><p align="justify">In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3.</p><p align="justify">&quot;Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints,&quot; said EU Competition Commissioner Joaquin Almunia.</p><p align="justify">&quot;The Commission will not tolerate such anticompetitive practices.&quot;</p><p align="justify">The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year.</p><p align="justify">The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan.</p><p align="justify">The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy.</p><p align="justify">The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming &quot;a club&quot; and &quot;a pile of $$$&quot; to be shared.</p><p align="justify">It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts.</p><p align="justify">The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson &amp; Johnson and Novartis. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

EU fines Ranbaxy, others for blocking cheaper drugs

-Reuters BRUSSELS: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market. The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said "pay-for-delay" deals lead to consumers paying as much as 20 percent more for their medicines. The EU action came two days after the US Supreme Court said that US regulators could challenge deals between brand-name drug companies and generic rivals because of the higher consumer costs. Pay-for-delay agreements involve brand-name firms paying generic companies not to deliver versions of their drugs, which usually cost a fraction of the original medicine, to market, although the issue is also complicated by patent ownership. In this case, Lundbeck was accused of paying other companies to have them delay delivering a generic version of its anti-depressant medicine citalopram to the market. Reuters first reported the fines on June 3. "Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints," said EU Competition Commissioner Joaquin Almunia. "The Commission will not tolerate such anticompetitive practices." The European Commission, which acts as competition regulator across the 27-member European Union, handed Lundbeck the largest fine totalling 93.8 million euros. As a result, Lundbeck cut its guidance for operating profits this year. The Commission fined Germany's Merck KGaA 21.4 million euros and handed a further 7.77 million euro fine jointly to Merck and its former subsidiary Generics UK, which is now owned by U.S. generic drugmaker Mylan. The other penalised companies were Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma - which is now part of Zoetis Products LLC, AL Industrier and India's No. 1 pharmaceutical company Ranbaxy. The Commission said the generic companies agreed with Lundbeck in 2002 not to enter the market in return for substantial payments, with internal company documents referring to forming "a club" and "a pile of $$$" to be shared. It said Lundbeck also bought generics' stock and destroyed it. Lundbeck said it would appeal the EU decision to the courts. The EU competition authority has two similar cases in the pipeline, involving Israel's Teva, French drugmaker Servier, Johnson & Johnson and Novartis.